Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Shunan Qi; Joachim Yahalom; Meier Hsu; Monica Chelius; Matthew Lunning; Alison Moskowitz; Steven Horwitz

doi:10.1080/10428194.2016.1180689

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Shunan Qi, Joachim Yahalom, Meier Hsu, Monica Chelius, Matthew Lunning, Alison Moskowitz, Steven Horwitz

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p < 0.001). Ethnicity had no prognostic difference. EN-NK/TCL-NT in non-Asians shared similar disease characteristics and treatment outcomes with Asians. Most early-stage patients have achieved durable remissions. Management of advanced-stage disease remains challenging, with frequent progression and high mortality.

Original language	English (US)
Pages (from-to)	2575-2583
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	57
Issue number	11
DOIs	https://doi.org/10.1080/10428194.2016.1180689
State	Published - Nov 1 2016
Externally published	Yes

Keywords

Drug therapy
SMILE
ethnology
extranodal NK-T-cell lymphomas
radiotherapy

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2016.1180689

Cite this

@article{8417489a7043457a98a09d1b15bb44a5,

title = "Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population",

abstract = "Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p < 0.001). Ethnicity had no prognostic difference. EN-NK/TCL-NT in non-Asians shared similar disease characteristics and treatment outcomes with Asians. Most early-stage patients have achieved durable remissions. Management of advanced-stage disease remains challenging, with frequent progression and high mortality.",

keywords = "Drug therapy, SMILE, ethnology, extranodal NK-T-cell lymphomas, radiotherapy",

author = "Shunan Qi and Joachim Yahalom and Meier Hsu and Monica Chelius and Matthew Lunning and Alison Moskowitz and Steven Horwitz",

note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2016",

month = nov,

day = "1",

doi = "10.1080/10428194.2016.1180689",

language = "English (US)",

volume = "57",

pages = "2575--2583",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "11",

}

TY - JOUR

T1 - Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

AU - Qi, Shunan

AU - Yahalom, Joachim

AU - Hsu, Meier

AU - Chelius, Monica

AU - Lunning, Matthew

AU - Moskowitz, Alison

AU - Horwitz, Steven

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p < 0.001). Ethnicity had no prognostic difference. EN-NK/TCL-NT in non-Asians shared similar disease characteristics and treatment outcomes with Asians. Most early-stage patients have achieved durable remissions. Management of advanced-stage disease remains challenging, with frequent progression and high mortality.

AB - Extra-nodal NK/T-cell lymphoma, nasal type (EN-NK/TCL-NT), is rare in the Western world. We launched the current single-institutional retrospective study with Institutional Review Board approval to better understand the disease. 43 EN-NK/TCL-NT patients treated from 1996 to 2014 were analyzed, including 10 (23%) Asians and 33 (76%) non-Asians. 19/26 (73%) early-stage patients received short-course chemotherapy followed by radiotherapy. 14/17 (82%) advanced-stage patients received primary chemotherapy. Complete response rate was significantly higher in the modified-SMILE group than the accelerated-CHOP group (80% vs. 30%, p = 0.015). The 2-year overall survival (OS) and progression-free survival (PFS) were 60% and 40%, respectively. Early-stage disease had significantly higher 2-year OS (87% vs. 21%) and PFS (56% vs.18%) than advanced-stage (p < 0.001). Ethnicity had no prognostic difference. EN-NK/TCL-NT in non-Asians shared similar disease characteristics and treatment outcomes with Asians. Most early-stage patients have achieved durable remissions. Management of advanced-stage disease remains challenging, with frequent progression and high mortality.

KW - Drug therapy

KW - SMILE

KW - ethnology

KW - extranodal NK-T-cell lymphomas

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84969228136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969228136&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1180689

DO - 10.1080/10428194.2016.1180689

M3 - Article

C2 - 27183991

AN - SCOPUS:84969228136

SN - 1042-8194

VL - 57

SP - 2575

EP - 2583

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 11

ER -

Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this